SOBI, INC
WALTHAM, DE

About Sobi Sobi is an international rare disease company dedicated to providing access to innovative treatments that make a significant difference for people with rare diseases. We have two business areas: Haemophilia and Specialty Care. Our research and product portfolio is primarily focused on haemophilia, inflammation, and genetic and metabolic diseases. In Haemophilia, we aim to take a leadership position in Europe, the Middle East and Africa. In Specialty Care, we provide treatments for rare diseases and specialty indications. Our experience and competence in rare disease and niche indications offers a platform from which we will continue to grow and provide continued and greater access to treatments for patients. Integrated biotechnology company Sobi is an integrated biotechnology company with in-house capabilities that encompass the entire value chain, from research, to preclinical and clinical development, biologics manufacturing and supply, to patient access and distribution. This integrated approach is a prerequisite for providing proprietary drugs, and an enabler for partnerships, especially at early stages of drug development. With our head office in Stockholm, Sweden, the Sobi organisation spans 25 countries, delivering treatments to patients in over 60 countries across the globe. Europe is the core market for the haemophilia franchise. We aim to expand our business further. Born 1965. BA Princeton University and MBA from Harvard Business School. Board member since 2012. CEO in b-business partners and Emerging Technologies AB. Board member of SAAB AB, IBX Group AB and Gambro Holding AB. Vice President, General Counsel, Emerging Markets at Takeda Pharmaceuticals 2015 - 2017. Senior Director and Senior Corporate Counsel, Takeda Pharmaceuticals, 2011-2015, Corporate Councel, Nycomed Pharma, 2004-2010, Corporate Councel, Ferring Pharmaceuticals, 2001-2004, Senior Associate/Lawer at Advokatfirman Lindahl, 1997-2001. Head of European Strategic Asset team, Haemophilia, and Business Unit Head Haemophilia, UK, Pfizer. Born 1967. Employed since 2017. Dipl. BW (FH)/Business Administrator, FH Rhenania Palatina/Mainz, Germany Global head of Cardiovascular business unit in Sanofi, Vice President Renal Europe and Head of Regional Liaisons, Sanofi, Vice President Renal and Endocrine Europe, Genzyme, General Manager Benelux Genzyme. Prior to Genzyme 13 years in Baxter. Born 1969. Employed since 2014. MBA from Rekanati Business School, Tel-Aviv University, Israel . BSc in Biology - Tel-Aviv University, Israel. Various senior roles within Merck since 1998, most recently as Vice President of Marketing (US). Managing Director Scandinavia, Global Marketing Head, Business Unit Manager. Product Manager, Schering AG. Corporate governance refers to the decision making systems through which the owners, directly or indirectly, govern the company. Good corporate governance requires ensuring that decision-making processes have been defined with a clear division of responsibilities and effective controls from all corporate bodies to all levels of the organisation, to ensure that they follow the company’s strategy in unison and act in pursuance of the company’s commercial goals. Swedish Orphan Biovitrum AB (publ) ("Sobi") is a Swedish public limited liability company with registered office in Stockholm, listed on Nasdaq Stockholm. Pursuant to its listing agreement with the Nasdaq Stockholm, Sobi has undertaken to observe the Swedish Code of Corporate Governance (the "Corporate Governance Code"). The Corporate Governance Code is based on the principle of "comply or explain", meaning that a company may deviate from the provisions set forth therein, provided that each such deviation is properly explained. The Corporate Governance Report describes Sobi’s corporate governance activities during the recent fiscal year The Annual General Meeting (AGM) in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, is held in the Stockholm area during the first half of the year. No later than at the publication of the third-quarter report, shareholders are informed of the time and place of the AGM and are provided information on their right to have business discussed at the AGM. The notice of the AGM is published at the earliest six weeks, but no later than four weeks, before the date of the AGM. The AGM is informed about the company’s development over the past fiscal year and decides on a number of central issues, such as changes the election of auditor, discharging the Board from liability for the fiscal year, remuneration for the Board and fees to the auditor, decisions on the number of Board members, election of the Board for the period up to the close of the next AGM and dividends. The name of the company is Swedish Orphan Biovitrum AB (publ). The company is a public limited liability company. The Board of Directors of the company shall have its registered office in Stockholm. The object of the company’s business shall be to carry out research, manufacturing business and trade, mainly within the pharmaceutical industry, and to pursue other business related thereto. The company’s share capital shall be not less than SEK one hundred and ten million (110,000,000) and not more than SEK four hundred and forty million (440,000,000). The series C shares are preference shares, which entitle the holder to a different distribution of the company’s profits than common shares. Series C shares only give entitlement to a fixed annual dividend equal to 10% of the company’s distributable profits, calculated on the quota value of the share. Common shares may be issued in a number of 100% of the total number of shares in the company. Series C shares may be issued in a number of not more than fifteen million (15,000,000) shares. Should the company decide to issue new common shares and series C shares through cash or set-off issue, holders of common shares and series C shares shall have pre-emptive rights to subscribe for new shares of the same series in proportion to the number of shares already held (primary pre-emptive right). Any shares not subscribed for on the basis of primary pre-emptive rights shall be offered to all shareholders for subscription (secondary pre-emptive right).